JP7393943B2 - リソソーム蓄積障害に関する医薬組成物及び使用 - Google Patents

リソソーム蓄積障害に関する医薬組成物及び使用 Download PDF

Info

Publication number
JP7393943B2
JP7393943B2 JP2019507811A JP2019507811A JP7393943B2 JP 7393943 B2 JP7393943 B2 JP 7393943B2 JP 2019507811 A JP2019507811 A JP 2019507811A JP 2019507811 A JP2019507811 A JP 2019507811A JP 7393943 B2 JP7393943 B2 JP 7393943B2
Authority
JP
Japan
Prior art keywords
acetyl
leucine
lsd
pharmaceutical composition
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019507811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524821A (ja
JP2019524821A5 (https=
Inventor
ミカエル ストラップ，
Original Assignee
イントラバイオ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7393943(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by イントラバイオ リミティド filed Critical イントラバイオ リミティド
Publication of JP2019524821A publication Critical patent/JP2019524821A/ja
Publication of JP2019524821A5 publication Critical patent/JP2019524821A5/ja
Priority to JP2022001694A priority Critical patent/JP2022050564A/ja
Publication of JP7393943B2 publication Critical patent/JP7393943B2/ja
Application granted granted Critical
Priority to JP2024027864A priority patent/JP7757446B2/ja
Priority to JP2025170034A priority patent/JP2025188157A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019507811A 2016-08-11 2017-08-11 リソソーム蓄積障害に関する医薬組成物及び使用 Active JP7393943B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022001694A JP2022050564A (ja) 2016-08-11 2022-01-07 リソソーム蓄積障害に関する医薬組成物及び使用
JP2024027864A JP7757446B2 (ja) 2016-08-11 2024-02-27 リソソーム蓄積障害に関する医薬組成物及び使用
JP2025170034A JP2025188157A (ja) 2016-08-11 2025-10-08 リソソーム蓄積障害に関する医薬組成物及び使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB1613828.1 2016-08-11
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GB1702552.9 2017-02-16
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GB1705762.1 2017-04-10
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GB1706854.5 2017-04-28
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022001694A Division JP2022050564A (ja) 2016-08-11 2022-01-07 リソソーム蓄積障害に関する医薬組成物及び使用

Publications (3)

Publication Number Publication Date
JP2019524821A JP2019524821A (ja) 2019-09-05
JP2019524821A5 JP2019524821A5 (https=) 2020-09-17
JP7393943B2 true JP7393943B2 (ja) 2023-12-07

Family

ID=59859423

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019507811A Active JP7393943B2 (ja) 2016-08-11 2017-08-11 リソソーム蓄積障害に関する医薬組成物及び使用
JP2022001694A Pending JP2022050564A (ja) 2016-08-11 2022-01-07 リソソーム蓄積障害に関する医薬組成物及び使用
JP2024027864A Active JP7757446B2 (ja) 2016-08-11 2024-02-27 リソソーム蓄積障害に関する医薬組成物及び使用
JP2025170034A Pending JP2025188157A (ja) 2016-08-11 2025-10-08 リソソーム蓄積障害に関する医薬組成物及び使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022001694A Pending JP2022050564A (ja) 2016-08-11 2022-01-07 リソソーム蓄積障害に関する医薬組成物及び使用
JP2024027864A Active JP7757446B2 (ja) 2016-08-11 2024-02-27 リソソーム蓄積障害に関する医薬組成物及び使用
JP2025170034A Pending JP2025188157A (ja) 2016-08-11 2025-10-08 リソソーム蓄積障害に関する医薬組成物及び使用

Country Status (30)

Country Link
US (4) US11400067B2 (https=)
EP (4) EP3482754B1 (https=)
JP (4) JP7393943B2 (https=)
KR (4) KR20220154849A (https=)
CN (3) CN109843275B (https=)
AU (3) AU2017308864B2 (https=)
CA (1) CA3033557A1 (https=)
CY (2) CY1121345T1 (https=)
DK (2) DK3359146T3 (https=)
ES (2) ES2849566T3 (https=)
FI (1) FIC20260014I1 (https=)
HK (1) HK1253282B (https=)
HR (2) HRP20190344T1 (https=)
HU (2) HUE052837T2 (https=)
IL (2) IL314107A (https=)
LT (2) LT3482754T (https=)
MA (2) MA43876B1 (https=)
MD (2) MD3359146T2 (https=)
ME (1) ME03340B (https=)
MX (2) MX384447B (https=)
NZ (3) NZ790895A (https=)
PL (2) PL3482754T3 (https=)
PT (2) PT3482754T (https=)
RS (2) RS61442B1 (https=)
RU (1) RU2749515C2 (https=)
SG (1) SG11201901048VA (https=)
SI (2) SI3359146T1 (https=)
SM (2) SMT202100050T1 (https=)
TN (1) TN2019000032A1 (https=)
WO (1) WO2018029657A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3359146T3 (en) * 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
EP3886986A1 (en) * 2018-12-06 2021-10-06 IntraBio Ltd Deuterated analogs of acetyl-leucine
SMT202400334T1 (it) * 2019-03-02 2024-09-16 Intrabio Ltd (n-)acetil-l-leucina per il trattamento di lesioni cerebrali traumatiche
RS67283B1 (sr) 2019-06-28 2025-11-28 Intrabio Ltd Kombinovana terapija sa acetil-leucinom i miglustatom za lečenje bolesti lizozomskog skladištenja
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
FR2883180B1 (fr) 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (en) * 2008-03-14 2009-09-17 Irm Llc Compounds, compositions and methods for treating lysosomal storage diseases and disorders
TN2010000251A1 (fr) 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
WO2018029658A1 (en) 2016-08-11 2018-02-15 Intrabio Limited Therapeutic agents for neurodegenerative diseases
DK3359146T3 (en) 2016-08-11 2019-04-08 Intrabio Ltd PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
JP2015518872A (ja) 2012-06-06 2015-07-06 フォンダッツィオーネ・テレソン アロステリックシャペロンおよびその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｎｅｕｒｏｌｏｇｙ，２０１５年，Ｖｏｌ．８５，Ｎｏ．１６，ｐｐ．１３６８－１３７５

Also Published As

Publication number Publication date
AU2023202903A1 (en) 2023-05-25
CY1121345T1 (el) 2020-05-29
SMT201900154T1 (it) 2019-05-10
ES2716133T3 (es) 2019-06-10
RU2021115932A (ru) 2021-06-08
US12433862B2 (en) 2025-10-07
LT3482754T (lt) 2021-05-10
NZ790894A (en) 2026-03-27
JP2025188157A (ja) 2025-12-25
CY1123844T1 (el) 2022-05-27
MD3482754T2 (ro) 2021-05-31
RS58478B1 (sr) 2019-04-30
IL314107A (en) 2024-09-01
EP3482754A1 (en) 2019-05-15
HRP20190344T1 (hr) 2019-04-19
CN109843275A (zh) 2019-06-04
US12433863B2 (en) 2025-10-07
RU2019106493A3 (https=) 2020-10-26
US20190201359A1 (en) 2019-07-04
CN121360108A (zh) 2026-01-20
FIC20260014I1 (fi) 2026-04-27
MX384447B (es) 2025-03-14
SI3359146T1 (sl) 2019-05-31
US20240197663A1 (en) 2024-06-20
NZ790895A (en) 2026-03-27
EP3482754B1 (en) 2020-12-23
US11400067B2 (en) 2022-08-02
PL3359146T3 (pl) 2019-07-31
IL264610B1 (en) 2024-08-01
MX2019001577A (es) 2019-08-29
SMT202100050T1 (it) 2021-03-15
HUE041914T2 (hu) 2019-06-28
KR20220044372A (ko) 2022-04-07
EP3359146A1 (en) 2018-08-15
ES2849566T3 (es) 2021-08-19
IL264610A (en) 2019-02-28
EP3865126A1 (en) 2021-08-18
KR20190039226A (ko) 2019-04-10
US20260027077A1 (en) 2026-01-29
HK1253282A1 (en) 2019-06-14
AU2017308864B2 (en) 2023-06-01
CA3033557A1 (en) 2018-02-15
KR20240110078A (ko) 2024-07-12
HRP20210153T1 (hr) 2021-05-28
MA43876A (fr) 2018-08-15
ME03340B (me) 2019-10-20
KR102412724B1 (ko) 2022-06-23
AU2025203479A1 (en) 2025-05-29
AU2017308864A1 (en) 2019-02-21
PL3482754T3 (pl) 2021-07-05
IL264610B2 (en) 2024-12-01
BR112019002719A2 (pt) 2019-05-14
SG11201901048VA (en) 2019-03-28
JP7757446B2 (ja) 2025-10-21
MX2021008432A (es) 2021-08-19
MD3359146T2 (ro) 2019-04-30
JP2019524821A (ja) 2019-09-05
PT3359146T (pt) 2019-03-27
MA55947A (fr) 2022-03-23
PT3482754T (pt) 2021-02-03
KR20220154849A (ko) 2022-11-22
RU2749515C2 (ru) 2021-06-11
WO2018029657A1 (en) 2018-02-15
LT3359146T (lt) 2019-04-25
TN2019000032A1 (en) 2020-07-15
AU2023202903B2 (en) 2025-03-06
JP2022050564A (ja) 2022-03-30
DK3359146T3 (en) 2019-04-08
RS61442B1 (sr) 2021-03-31
EP4342461A2 (en) 2024-03-27
HK1253282B (en) 2020-02-07
SI3482754T1 (sl) 2021-04-30
DK3482754T3 (da) 2021-02-01
CN121360107A (zh) 2026-01-20
KR102467953B1 (ko) 2022-11-16
CN109843275B (zh) 2026-04-24
NZ750391A (en) 2026-03-27
EP4342461A3 (en) 2024-05-29
RU2019106493A (ru) 2020-09-11
MA43876B1 (fr) 2019-04-30
HUE052837T2 (hu) 2021-05-28
JP2024059863A (ja) 2024-05-01
US20220331278A1 (en) 2022-10-20
EP3359146B1 (en) 2019-01-23

Similar Documents

Publication Publication Date Title
AU2023202121B2 (en) Therapeutic agents for neurodegenerative diseases
JP7757446B2 (ja) リソソーム蓄積障害に関する医薬組成物及び使用
RU2853626C2 (ru) Фармацевтические композиции и применения против лизосомных болезней накопления
HK40101408A (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
HK40050066A (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
BR112019002719B1 (pt) Uso de uma acetil-leucina ou um sal farmaceuticamente aceitável da mesma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200806

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200806

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220107

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220107

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220316

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220318

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220408

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230825

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231127

R150 Certificate of patent or registration of utility model

Ref document number: 7393943

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150